Triple Therapy in Chronic Obstructive Pulmonary Disease: Consideration Under New Evidence
Chronic obstructive pulmonary disease (COPD) is one of the most prevalent chronic airway diseases globally, with a significant burden on public health. In China alone, recent epidemiological surveys estimate that as many as 100 million people are affected by COPD, placing it on par with other major chronic conditions such as hypertension and diabetes. Given its widespread impact, COPD has been prioritized in the “Action Plan of Healthy China 2030,” emphasizing the need for effective long-term management strategies. The primary goals of COPD treatment include symptom relief, prevention and management of exacerbations, halting disease progression, and reducing mortality.
The evolution of pharmacological therapies for COPD over the past five decades has been remarkable. In the 1960s, short-acting bronchodilators, oral theophylline, and mucolytics were the mainstays of treatment. By the 1990s, the introduction of inhaled corticosteroids (ICS) combined with long-acting beta-agonists (LABA) (ICS/LABA) marked a significant advancement. The 2000s saw the emergence of long-acting muscarinic antagonists (LAMAs) and more potent LABAs. Since 2010, the development of fixed triple therapy (ICS/LABA/LAMA) in a single inhaler has revolutionized COPD management. This progression has been driven by the persistent challenges faced by many COPD patients, including ongoing symptoms, frequent exacerbations, and disease progression despite optimal medical therapy.
The advent of fixed-dose triple therapy in a single inhaler has transformed the approach to inhaled treatment. Numerous double-blind, international, multicenter, randomized controlled trials have demonstrated the superiority of triple therapy over dual therapies. These studies have shown that triple therapy significantly reduces the risk of COPD exacerbations, improves symptom control, slows disease progression, enhances lung function, and may even reduce all-cause mortality. Key trials such as TRIBUTE, IMPACT, and KRONOS have provided robust evidence supporting these benefits. For instance, the TRIBUTE trial found that triple therapy led to a 15% reduction in moderate-to-severe exacerbations compared to dual bronchodilator therapy. Similarly, the IMPACT trial showed a 25% reduction in exacerbation rates and a 42% reduction in all-cause mortality with triple therapy compared to ICS/LABA.
However, the application of triple therapy in clinical practice requires careful consideration due to the heterogeneity and complexity of COPD. The disease manifests in various phenotypes, including chronic bronchitis, emphysema, frequent exacerbators, and COPD-asthma overlap. Disease severity, exacerbation frequency, and progression patterns also vary widely among patients. This diversity underscores the need for personalized treatment strategies to optimize outcomes, minimize treatment burden, and reduce adverse effects.
Clinical trials of triple therapy have primarily included patients with high symptom burden (COPD Assessment Test [CAT] score ≥10) and moderate-to-very severe airflow limitation. Most trials have also focused on patients with an increased risk of exacerbations (at least one moderate-to-severe exacerbation per year) despite receiving LAMA, LABA/LAMA, or LABA/ICS therapy. Additionally, these trials have included COPD patients with a history of asthma. For example, further analysis of the TRIBUTE and IMPACT trials revealed that the reduction in exacerbation rates with triple therapy was most pronounced in the first month of treatment, with no significant differences observed in the subsequent 11 months. This early benefit may be attributed to the inclusion of patients with a history of asthma or prior ICS use, suggesting that triple therapy may be particularly beneficial in these subgroups.
Blood eosinophil counts have emerged as a potential biomarker for predicting treatment response to ICS-containing triple therapy. Studies have shown that patients with higher blood eosinophil counts (≥100 cells/μL) are more likely to benefit from ICS-containing regimens. However, the evidence supporting this association is largely derived from post-hoc analyses of clinical trials, necessitating further validation in specifically designed randomized controlled trials. The reproducibility and optimal threshold of blood eosinophil counts remain under debate, as these counts can be influenced by various factors. Moreover, exacerbations associated with increased eosinophil levels (eosinophilic exacerbations) may be more responsive to ICS-containing triple therapy, while bacterial-associated exacerbations may be less responsive and carry an increased risk of pneumonia. Emerging evidence suggests that patients with low blood eosinophil counts (<100 cells/μL) are at higher risk of pneumonia when treated with ICS-containing therapy, highlighting the need for precise biomarkers to guide treatment decisions.
The Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2020 guidelines recommend triple therapy as a step-up from LAMA/LABA or LABA/ICS in patients who continue to experience exacerbations and significant breathlessness despite maintenance therapy. Specifically, ICS can be added to LABA/LAMA therapy in patients with blood eosinophil counts ≥100 cells/μL, with a greater likelihood of response at higher eosinophil levels. In patients on LABA/ICS therapy, LAMA can be added to escalate to triple therapy if symptoms persist or exacerbations occur. Conversely, ICS can be discontinued in patients on triple therapy if side effects (e.g., pneumonia) warrant discontinuation or if there is a lack of response to ICS treatment. Patients with eosinophil counts >300 cells/μL should be closely monitored for exacerbation relapse following ICS withdrawal.
In certain scenarios, triple therapy may be considered as a first-line treatment rather than an escalation therapy. For instance, patients discharged from the hospital after a severe COPD exacerbation, with a history of frequent exacerbations and blood eosinophil counts ≥300 cells/μL, may benefit from triple therapy initiation. These patients are at high risk of re-hospitalization and may derive significant benefit from early triple therapy. Similarly, patients newly diagnosed with severe airflow obstruction (forced expiratory volume in one second <50%), who are symptomatic, at high risk of exacerbations (≥2 moderate exacerbations or ≥1 hospitalization in the previous year), and have high eosinophil counts (≥300 cells/μL) or a history of asthma, may also be candidates for first-line triple therapy. Dynamic assessment of treatment response and timely adjustment of regimens are essential in these cases.
In conclusion, triple therapy has demonstrated superior efficacy in improving symptoms, lung function, and reducing exacerbation risk and disease progression compared to dual therapies. It also shows promise in reducing all-cause mortality. However, the heterogeneity of COPD necessitates further research to identify patients most likely to benefit from triple therapy and those less responsive to ICS. Current evidence supports the use of triple therapy in patients with frequent or severe exacerbations, those who have received dual bronchodilators or LABA/ICS therapy, and those with a history of asthma or high blood eosinophil counts (≥300 cells/μL). Clinicians should carefully assess treatment response and potential side effects, discontinuing ICS if adverse effects occur, to optimize COPD management and minimize pharmacological burden.
doi.org/10.1097/CM9.0000000000001340
Was this helpful?
0 / 0